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Abstract
Adjuvant therapy of stage IIB/III melanoma with interferon reduces relapse and mortality by up to 33% but is accompanied
by toxicity-related complications. Polymorphisms of the CTLA-4 gene associated with autoimmune diseases could help in
identifying interferon treatment benefits. We previously genotyped 286 melanoma patients and 288 healthy (unrelated)
individuals for six CTLA-4 polymorphisms (SNP). Previous analyses found no significant differences between the
distributions of CTLA-4 polymorphisms in the melanoma population vs. controls, no significant difference in relapse free
and overall survivals among patients and no correlation between autoimmunity and specific alleles. We report new analysis
of these CTLA-4 genetic profiles, using Network Phenotyping Strategy (NPS). It is graph-theory based method, analyzing the
SNP patterns. Application of NPS on CTLA-4 polymorphism captures allele relationship pattern for every patient into 6-
partite mathematical graph P. Graphs P are combined into weighted 6-partite graph S, which subsequently decomposed
into reference relationship profiles (RRP). Finally, every individual CTLA-4 genotype pattern is characterized by the graph
distances of P from eight identified RRP’s. RRP’s are subgraphs of S, collecting equally frequent binary allele co-occurrences
in all studied loci. If S topology represents the genetic ‘‘dominant model’’, the RRP’s and their characteristic frequencies are
identical to expectation-maximization derived haplotypes and maximal likelihood estimates of their frequencies. The graph-
representation allows showing that patient CTLA-4 haplotypes are uniquely different from the controls by absence of
specific SNP combinations. New function-related insight is derived when the 6-partite graph reflects allelic state of CTLA-4.
We found that we can use differences between individual P and specific RRPs to identify patient subpopulations with clearly
different polymorphic patterns relatively to controls as well as to identify patients with significantly different survival.
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Introduction
Adjuvant therapy of patients with stage IIB/III melanoma
(high-risk) with interferon was approved by FDA (United States
Food and Drug administration) and subsequently by regulatory
authorities worldwide [1]. Despite the ability of this regimen to
reduce relapse and mortality by up to 33% [2–4] acceptance has
been limited due to toxicity of this regimen. Attempts to identify
the subset of patients destined to benefit from adjuvant treatment
with IFNa-2b have failed to discover clinical or demographic
features of the patient population that are capable of predicting the
benefit from high dose interferon (HDI) therapy. Correlative
studies have been undertaken over the years, demonstrating a
variety of immunological responses subsequent to therapy [5,6].
We recently published a paper in which six CTLA-4
polymorphisms were evaluated in a cohort of patients treated
with adjuvant interferon [7]. The human CTLA-4 gene is located
on chromosome 2q33, in a region that is associated with
susceptibility for autoimmune disease [8] and multiple polymor-
phisms of the CTLA-4 gene have been found to be associated with
susceptibility to autoimmune diseases (e.g. the GG allele of the +49
AG polymorphism is associated with decreased expression of
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CTLA-4 upon T-cell activation and thus a higher proliferation of
T-cells) [9–12].
We genotyped DNA isolated from the peripheral blood of a
total of 286 patients with high-risk melanoma who participated in
a prospective multicenter randomized phase III trial of adjuvant
interferon and a panel of 288 randomly selected healthy unrelated
Greek individuals from the Donor Marrow Registry of the
National Tissue Typing Center, Athens, Greece that served as a
control population for 6 CTLA4-SNPs of potential interest –
namely CT 60, AG 49, CT 318, JO 27, JO 30 and JO 31. CT 318
is located within the promoter region of the CTLA-4 gene, A/G49
is located at exon 1, while the rest of the SNPs tested are located at
the 39 untranslated region of CTLA-4.
High levels of association among the different polymorphisms
were found (Fisher’s exact p value,0.001 for all associations).
Genotypes corresponding to the six CTLA-4 polymorphisms did
not significantly deviate from the Hardy-Weinberg equilibrium.
This indicates significant linkage disequilibrium among the six
polymorphisms. We analyzed the segregation pattern of CT 318,
AG 49, CT 60, JO 27, JO 30, JO 31 SNPs on 572 chromosomes
and identified 5 major haplotypes. No statistically significant
differences for relapse free survival or overall survival were found
for the presence of each of the 3 most common haplotypes. When
the respective polymorphisms were considered separately for
outcome analysis by the allele status, or when the three most
significant haplotypes were considered, two results emerged:
1. No significant differences were found between the distributions
of CTLA-4 polymorphisms in the melanoma population
compared with healthy controls.
2. Relapse free survival (RFS) and overall survival (OS) did not
differ significantly among patients with the alleles represented
by these polymorphisms. No correlation between autoimmu-
nity and specific alleles was evident.
The results reported in the original paper [7] considered
‘‘dominant model’’ in which both homozygous and heterozygous
copies of the six assayed SNP loci were assumed to have similar
effect on altering the CTLA-4 function.
We use the original experimental genotyping results on CTLA-4
genotype profile as risk factor as the basis for the new analysis
designed and undertaken in this paper. A novel general method of
pattern analysis, referred below as network phenotyping strategy
(NPS), was introduced for integrative, relationship-based analysis
of clinical data [13–15]. In the particular application described in
this paper, NPS replaces analysis of CTLA-4 individual alleles and
allele frequencies by the analysis of relationships between CTLA-4
alleles for every individual in the study. NPS solves two types of
problems: First, the ‘‘power’’ problem is addressed, which
complicates the use of methods that approach such complete-
relationship based analysis by using large number of interaction
terms, which requires large number of subjects for informative
statistical analyses. NPS captures instead the actual polymorphism
relationship patterns cumulatively into special mathematical
graphs. Second, NPS-processing of genotyping data eliminates
using a priori hypothesis about the role of homozygous and
heterozygous allelic forms of the studied genomic variants. Graph-
theory based representation of the genotyping results through NPS
provides unifying quantitative representation of the complete
status of all CTLA-4 variants individually for each patient. In our
CTLA-4 genotyping data, we thus do not analyze independent
interrelationships among the 153 possible combinations of AA, AB
and BB alleles of the six studied CTLA-4 polymorphism. Instead,
we take advantage of the fact that all those 153 relationships can
be captured in a single relationship pattern graph. A path in this
graph then encodes the actual complete experimental CTLA-4
genotyping results for every studied subject. In this way, the
complete information about all allele relationships for an
individual is captured by a single mathematical object. An
important property of the NPS analysis is that, from the collection
of all individual SNP relationship patterns, we can additionally
compute (in a deterministic, non-statistical way) a framework of
directly clinically and functionally interpretable reference relation-
ship profiles (RRP). These RRP’s represent ‘‘landmarks’’ in the
(multidimensional) clinical/genotypic relationship data space. The
clinical significance of the RRP landmarks is then measurable in
terms of how many patients have close (but not necessarily
identical) personal CTLA-4 genotype relationship patterns to
those ‘‘landmarks’’. For the concrete example of CTLA-4
polymorphisms studied in this paper, RRP’s represent limiting
characterization of the CTLA-4 SNP co-occurrence patterns. The
main advantage of the NPS approach is its identification of any
significant heterogeneity that might be captured in the data from
the clinical, or in this case the CTLA-4 based immune regulation
mechanism that we focused upon in this study of subjects with and
without melanoma. These results can be then used in designing
follow-up clinical studies.
Materials and Methods
Materials
Genotyping of DNA isolated from the peripheral blood of a
total of 286 patients with melanoma and a panel of 288 randomly
selected healthy unrelated Greek individuals that served as a
control population was described in detail previously. Details of
the institutional review board and ethics committee approval have
previously been published [16]. Six CTLA-4 SNPs were studied,
namely CT 60 (rs3087243), AG 49 (rs231775), CT 318
(rs5742909), JO 27 (rs11571297), JO 30 (rs7565213) and JO 31
(rs11571302). CT 318 is located within the promoter region of the
CTLA-4 gene, A/G49 is located at exon 1, while the rest of the
SNPs tested are located at the 39 untranslated region of CTLA-4.
Methods
Characterization of personal CTLA-4 genotype
relationship pattern by 6-partite graphs: Identifying the
part of the study data in which we have maximal
information to extract additional components of
information. We present two levels of CTLA-4 genotype
analysis. In the first one, we do not distinguish between
homozygous or heterozygous status of the six alleles. In the
second one, we will expand the genotype characterization using
the known zygosity of the six SNP’s. Fig. 1a shows how an
observed CTLA-4 genotype for one patient may be represented by
a 6-partite graph that will be called a personal relationship profile
prp, which we use for the purpose of the first analysis type,
considering the major/minor allele relationships only (Fig. 1a). In
Fig. 1b we define the type of personal relationship profile, for
which symbol PRP is used to emphasize that allele relationships
include observed allele zygosity. In both these representations,
each assayed SNP is represented by one of six partitions in the prp
or PRP. Each partition contains two or three vertices, representing
the allele for a given polymorphism (a= major allele, b= minor
allele in prp, a= major homozygous, ab= heterozygous, b=
minor homozygous allele in PRP). Edges in both graphs connect
only those vertices in different partitions that represent observed
(genotyped) alleles in the two different polymorphic sites. The
complete CTLA-4 genotype profile for an individual is then a
Mathematical Model Evaluating CTLA-4 Polymorphisms
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collection of edge-connected vertices in prp/PRP, forming a cycle
in prp/PRP. Because the edges in prp/PRP represent relation-
ships between the allelic states of the studied SNP’s, there is clear
meaning for each segment of the CTLA-4 genotype illustrated in
the hexagonal cycle. We can understand these lines in as
conditional relationships of type ‘‘if AG49 contains minor allele
then CT60 contains also minor allele and J031 contains minor
allele and then …. ‘‘. Note that the experimentally defined cycle in
e.g. prp represents not only the pair wise conditional relationships
shown by lines such as (AG49 =b when CT60 =b), but also all
other co-occurrences such as (AG49 =b when JO30 =b) etc. The
prp/PRP cycle representation of the CTLA-4 SNP allele status
co-occurrences is the simplest one capturing all co-occurrence
relationships while maintaining convenient mathematical simplic-
ity.
Collective characterization of CTLA-4 genotype profile
distribution in a cohort by cumulative weighted 6-partite
graph G. While PRP’s are exact ‘‘qualitative’’ representation of
the studied polymorphism relationship patterns in CTLA-4, we
need to convert this qualitative information into quantitative
characterization of these individual relationship patterns. It has
been shown by exact mathematical theorem [17] that the maximal
quantitative information captured by graphs is obtained when
PRP’s are compared to one another in graphs of the same type,
which we call reference relationship patterns (RRP). Therefore,
the next step of NPS transformation of the CTLA-4 polymorphism
relationship patterns into quantitative descriptors is to use the
actual data to derive the 6-partite graphs, representing the RRP’s
we need.
For this purpose, the individual prp or PRP graphs, describing
the SNP co-occurrences for all subjects were assembled into
cumulative 6-partite ‘‘study graphs’’ g and G. By adding every
individual patient CTLA-4 genotype profile representation prp to
the cumulative g graph, the weightings of every edge in g is
increased by one, and similarly but independently for PRP’s and
G. As a consequence of this construction, these g and G graphs
will have weighted edges defined by the co-occurrence frequencies
of all SNP pairs. The distribution of all individual CTLA-4
genotype profiles in case cohort is now represented by graph g.
In Fig. 2, the relative edge weights, resulting from adding all
individual case graphs prp and PRP to g and G, respectively, are
graphically represented by the variable relative thickness of the
edge lines. By converting these edge counts to frequencies,
statistical interpretation of the basic vertex-weighted edge-vertex
(a–b), (a–a), (b–a) and (b–b) motifs in study graphs is obtained.
The weights of study graph edges connecting, for example, the
major and minor allele vertices in the AG49 and CT60 partitions
define the estimates of the following conditional probabilities:
a{b*P AG49?aDCT60?bð Þ
a{a*P AG49?aDCT60?að Þ
b{a*p AG49?bDCT60?að Þ
b{b*P AG49?bDCT60?bð Þ
In the next step, the complete sets of reference
relationship patterns for CTLA-4 genotypes in both study
graphs g and G are identified and in case of g identified as
haplotypes. Haplotype is defined as a series of polymorphisms
in CTLA-4 genotype profile that are co-occurring with identical
probabilities, P(1),P(2), … ,P(6). Using the conditional
probability interpretation of edges in the study graphs shown in
above example, we can derive from the Bayes’ theorem, that if
sub-graphs of the study graph with equal weights (co-occurrence
frequency components) are found, the condition of P(1),P(2),…
, P(6) is automatically fulfilled. Thus, in our representation, a
complete set of haplotypes is represented by all RRP cycle
subgraphs with equal weights of all edges, which can be found in g
or G by ‘‘greedy’’ algorithm (Fil S1 and Figure S1).
For validation of this study graph-based approach to haplotype
identification, established procedures were additionally used where
the maximum likelihood estimates of haplotype frequencies given
a multi-locus sample of genetic marker genotypes [3 different
genotypes of the 6 polymorphisms] were generated using the
expectation-maximization (EM) algorithm under the assumption
of Hardy-Weinberg equilibrium (HWE). Linkage disequilibrium
was explored for each pair of the 6 polymorphisms (PROC
HAPLOTYPE). SAS 9.1 (SAS Institute Inc., Cary, NC, USA),
was used for the statistical analysis (reported in [7]).
Quantitative characterization of differences of personal
CTLA-4 genotype profiles prp and PRP from haplotypes,
Figure 1. Example how experimentally determined CTLA-4
genotype (top panel) for a patient (id =55) is transformed into
a) prp graph and b) PRP graph. a-major allele, b-minor allele, ab-
heterozygous allele status vertices. Each SNP is represented by a graph
partition (rectangles), identified by the SNP code. Lines – graph edges,
representing the co-occurrences of all alleles in the patient’s CTLA-4
genotype.
doi:10.1371/journal.pone.0086375.g001
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represented by rrp’s and RRP’s. For the quantification of the
graph-graph distances between individual patient relationship
patterns and haplotype-reference relationship patterns, we use the
mathematical results of [17,18], showing that one of the possible
definitions of graph-graph distances with all necessary mathemat-
ical properties is obtained simply by counting the number of edge
mismatches between the two graphs, as is shown by example in
Fig. 3. As the result, with haplotype decomposition of study graph
g resulting in 8 haplotype components, each subject (j) is
characterized by an 8-element vector ~dj~ dj 1ð Þ,dj 2ð Þ, . . . ,dj 8ð Þ
 
of eight distances of the personal CTLA-4 genotype profile from
compositions of all 8 respective haplotypes identified. Difference
vectors~dj were computed for all patients and controls using a) the
control cohort-defined haplotypes and b) the case cohort-defined
haplotypes.
Developing the hierarchical model for differentiating
between healthy controls and melanoma cases using the
CTLA-4 based personal genotype profiles from
haplotypes. Weka package (v. 3-6-6) implementation of J48
pruned tree algorithm was used to construct optimal model
recognizing the controls from cases using personal difference
vectors ~dj . Ten-fold cross-validation was used and characterized
the model quality by confusion matrices and ROC parameters.
Results
Fig. 4 shows decomposition of the g graphs for healthy controls
(Fig. 2a) and melanoma cases (Fig. 2b) into component cycles
rrpi, representing the haplotypes derived from individual geno-
typed profiles, containing CT60 (rs3087243), AG49 (rs231775),
CT318 (rs5742909), JO27 (rs11571297), JO30 (rs7565213) and
JO31 (rs11571302) SNPs.
Decomposing the 6-partite graph G constructed with explicit 3
allele states resulted in 20 RRP. We then computed a 20-
component vector of distances ~dj for every personal CTLA-4
genotype relationship pattern from all 20 RRP’s.
Results for study graph g
In both cohorts, the respective g graphs were decomposed into 8
cycles rrpi (i=1…8). Interestingly (and importantly) the three
haplotype graphs with the largest frequency were identical for
control and case cohorts. Table 1 shows that our g-based graph
algorithm also identified the same dominant haplotypes and
comparable frequencies of occurrence as the statistical algorithm
in (PROC HAPLOTYPE). SAS 9.1 (SAS Institute Inc., Cary, NC,
USA).
A unique feature of this approach in comparison to the analysis
of differences in haplotype frequencies that were tested in our
previous paper is that we can quantitatively characterize the
difference of the individual genotype profile from ‘‘averaged’’
CTLA-4 haplotype profiles. Fig. 3 demonstrates the meaning of
the differences. In this example, patient’s P55 CTLA-4 genotype
profile captured into ppr(55) matches the composition of the
graph representation of haplotype rrp3 in just three edges, thus
the d55 3ð Þ is 3. In the second example, CTLA-4 genotype profile
of the same patient is compared to C2 haplotype. Here no edges in
ppr(55) coincide with those of rrp2, thus the d55 2ð Þis 6. This is the
example of maximal difference between any haplotype subgraph
rrpi and individual CTLA-4 genotype profile prp(j) that can be
found in g.
Fig. 5 explains the main finding of this paper. Top level of
CTLA-4 genotype profile-based differentiation between cases and
controls is related to SNP pattern rrp8 = (bbabab) for (CT318-
AG49-CT60-JO30-JO27) cycle (see Fig. 4 and 5). 77% of
melanoma cases (219 patients) are recognized from healthy
controls by the ABSENCE of the rrp8 = (bbabab) allele pattern
for (CT318-AG49-CT60-JO30-JO27) SNP cycle. By surveying all
219 CTLA-4 individual genotype profiles for patients
withdi 8ð Þ~6 it was found that all have one of the five co-
occurring patterns, shown by solid line cycles in Fig. 5a–e. By
overlaying the rrp8 = (bbabab) case-control differentiating
pattern (dashed line cycles) over these actual case-specific genotype
profiles it is shown that the rrp8 pattern does not share any
relationship with these 5 melanoma-characteristic CTLA-4 SNP
co-occurrence patterns, indicating the possibility of disease risk
identification not by presence, but actually absence of specific
genotype profile. Graph mathematics opens the previously
overlooked half of the marker identification ‘‘Universe’’ – allowing
us to study invariants (such as our personalized differences of
CTLA-4 genotype profiles from the haplotype reference) and
identifying multiple SNP relationship patterns that share certain
properties (simultaneous presence or absence of a specific
combination of parameters).
Results for study graph G
The first information that comes from NPS-graph of the CTLA-
4 genotype considering the ‘‘collective allelic status’’ of all six
studied SNP’s (see Fig. 2b). With exception of CT318, there is a
strong preference for ‘‘allelic state conservation’’ in all remaining
Figure 2. Study graphs g (a) and G (b) constructed as union of all prp’s (g) or PRP’s (G). Symbols as in Fig. 1, thickness of edges in g and G are
proportional to co-occurrence frequencies of respective SNP pairs, connected by the edge.
doi:10.1371/journal.pone.0086375.g002
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loci: most frequent allelic status for (CT318-AG49-CT60-JO30-
JO27) SNP is heterozygous (a-ab-ab-ab-ab-ab) profile, the
second most frequent is profile with all homozygous wild-type
alleles, followed by homozygous (a-b-b-b-b-b) profile. Subjects
who had mixed type zygosity (a-ab-a-b-a… etc) CTLA-4 profiles
are minority in this study cohort. Because it was known that there
are no characteristic simple CTLA-4 genotype patterns that would
differentiate healthy controls from melanoma cases, we instead
looked for differences in distances from the all possible
RRP12RRP20 pairs that would maximize the separation of the
two sub-cohorts. The motivation for this approach is as follows:
The pattern-based genotype data transformation captures more
details of inter-subject differences in genetic status of CTLA-4 than
can be captured by any conventional analytical approach. This
information enhancement can be further increased by explicitly
considering the actual allele statuses. as discussed above, the
identification of the clinically relevant context relationship CTLA-
4 genotype pattern is obtained by looking for a higher frequency of
patients or controls with smaller distances from selected RRP’s,
relative to others.
An element of the ~dj vector characterizes the distance of the
personal CTLA-4 genotype pattern from reference, but does not
include directionality and distances of the personal CTLA-4
genotype pattern from other reference patterns. To include that
information into processed data, we therefore computed a
complete set of 190 pairwise distance differences~di{~dj , with i
and j going through all 20 elements of the CTLA-4 differences
from the four maximally case-control biased reference patterns
RRPi–RRPj identified in Fig. 6. These differences include
directionality of the closeness of the personal genotype to one of
the reference genotype patterns: D ijð Þ~dRRPi kð Þ{dRRPj kð Þ can
be positive or negative. Assume thatdRRPi kð Þ
=27,dRRPj kð Þ~{3.ThenD ijð Þ~{7{({3)~{4v0. Thus,
D ijð Þv0 indicates that a personal CTLA-4 genotype profile is
closer to RRji while D ijð Þ§0 indicates that personal CTLA-4
genotype profile is closer to RRPi and D ijð Þ~0 means that the
personal CTLA-4 genotype profile has the same number of
differences when compared either to reference profile RRPi or
RRPj. We computed the D ijð Þ using distances from all 190
possible RRP’s pairs, separately for cases and controls and
averaged them for each sub-cohort, obtaining case mean Dp ijð Þ
and control mean Dc ijð Þ for each RRP’s pair. Plotting these case
and cohort averages against each other in the two-dimensional
scheme allows direct identification of the reference CTLA-4
genotype pattern combinations that separate maximally the two
sub-cohorts. For uniformly or randomly distributed CTLA-4
genotype pattern positions we obtain Dp ijð Þ~Dc ijð Þ seen in the
2D plot as the diagonal y= x line. The combinations with
maximal Dp ijð ÞwDc ijð Þ or Dp ijð ÞvDc ijð Þ, which are the desired
clinically characteristic contexts will be in the 2D plot maximally
distant from the diagonal. Fig. 6 shows the resulting 2D plot with
the extreme combinations of the references indicated. The region
of D ijð Þ smaller than 0.5 is not considered, as there the subject’s
CTLA-4 genotype patterns are on average equally distant from
both reference pairs.
Fig. 7 shows histogram of patients with observed valued of
D ijð Þ. The patient or control distribution in the CTLA-4 genotype
pattern space is not uniform or normal. We see clear heteroge-
neity: In both groups, there are three main patient subgroups.
One, common for cases and controls has CTLA-4 genotypes
equally different from all reference CTLA-4 allele relationships
(central peak). Then there are two groups with their individual
Figure 3. Three examples showing how elements of distance
vectors ~djare computed for the same patient #55. In all figures,
prp (RRP in c)) for this patient = dashed lines, rrp’s (or RRP in c)) =
solid lines. Double arrows indicate mismatch in SNP co-occurrences.
Elements of~dj are sums of these mismatches (in computations, we add
negative sign to make identity (zero mismatches) mathematically
largest). a,b) Comparison of patient’s genotype to the second and third
reference SNP relationship patterns rrp3 and rrp2. c) Comparison of
patient’s genotype to the 4th reference SNP relationship pattern RRP4.
doi:10.1371/journal.pone.0086375.g003
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CTLA-4 genotype patterns significantly closer to one than to the
other reference genotype relationship network.
Fig. 8 shows the actual composition of these reference CTLA-4
genotype patterns for cases and controls. For controls, the
dominant reference CTLA-4 genotype pattern is all major allele
combination (RRP2) while for cases, RRP1 dominates, where
majority of studied CTLA-4 polymorphisms are in the heterozy-
gous state. This heterogeneity might be utilized in focused
prospective study of patients within the three subgroups identified:
One being characterized by the minimally genetically affected
CTLA-4, another having majority of CTLA-4 polymorphisms
with heterozygous state and the third with mixed CTLA-4
genotype relationship patterns, equally different from the two
extremes. It is clear that, contrary to melanoma patients, the
healthy biosystem of controls can accommodate the CTLA-4
genetic variation where a majority of studied polymorphisms relate
to the minor allele states that are identified as reference contexts
for two groups with CTLA-4 genotype patterns different from
‘‘normal’’ RRP2.
Figure 4. Decomposition of study graphs g (picture represents both cases and control subcohorts) into rrp’s 1–8. Case rrp’s are shown
by solid, control by dashed edges. Coefficients show the multiplicities of respective rrp’s in the g-decompositions (top = case graph, bottom =
control graph). Symbols as in Fig. 1.
doi:10.1371/journal.pone.0086375.g004
Table 1. CTLA-4 most frequent haplotypes identified by two methods – using HAPLOTYPE procedure in SAS (ref. [5]) and from
multiplicity of rrp’s in decomposition of study graph g.
AG49 CT60 CT318 JO27 JO30 JO31
CTLA-4 haplotype
frequencies from ref.[5]
rs231775 rs3087243 rs5742909 rs11571297 rs7565213 rs11571302 Frequency [%]
Standard
Error
Haplotype
frequency
using rrp’s – this
work [%]
A A C C A T 46.99 2.089 45.7
G G C T G G 29.34 1.91 23.0
A G T T G G 9.77 1.24 10.2
A G C T G G 6.49 1.031 6.0
A G C C A T 2.81 0.69 2.5
doi:10.1371/journal.pone.0086375.t001
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Figure 5. Case-control discrimination by ‘‘missing’’ CTLA-4 genotype reference profile rrp8 (dashed lines in all figures). Solid lines in
schemes a) – e) show five prp CTLA-4 genotype profiles, found exclusively for 219 (77%) patients identified from the complete case cohort by
condition that their prp have maximal possible distance from the rrp8. Symbols as in Fig. 1.
doi:10.1371/journal.pone.0086375.g005
Figure 6. Selection of maximally case-control survival discrim-
inating combination of distances from all RRP’s. Points are
defined by the Dp ijð Þ,Dc ijð Þ
 
coordinates (see text) computed by
averaging the distance differences over all patients separately in case
and control sub-cohorts for all 190 possible RRP pairs. In the
neighborhood of diagonal line Dp ijð Þ~Dc ijð Þ are non-discriminatory
combinations. The two lines are used to identify the combinations, with
maximal case – control and control-case bias in PRP-RRP distances. The
optimal selection is shown by boxes.
doi:10.1371/journal.pone.0086375.g006
Figure 7. Histograms showing heterogeneity of distributions of
individuals shown in the CTLA-4 genotype landscape, defined
by the inter-personal differences in prp’s for the five most
discriminating RRP combinations. Two selected combination of
dj ið Þ{dk ið Þ distance differences are plotted on x and y axes, on the z
axis are numbers of subjects having a given combination of the
distance differences. Blue-controls, red-cases.
doi:10.1371/journal.pone.0086375.g007
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Differentiation of the CTLA-4 genotype contexts
between the long and short surviving sub cohorts of
melanoma patients
Out of the 286 melanoma cases, we had 282 with survival data.
Characterization of the possible differences between the long- and
short-surviving patients now requires a different analysis strategy.
First, we tested the choice of CTLA-4 genotype reference
relationship patterns. After separate testing of results from NPS
analysis of melanoma case CTLA-4 genotype relationship profiles,
we found the simplest and statistically most significant results were
obtained when the RRP12RRP20 resulting from the analysis of
combined case/control cohort were used. That makes sense in
light of previous standard statistical analysis indicating no
significant differences in the actual CTLA-4 genotype patterns.
A larger cohort combined from cases and controls provided better
coverage of the possible reference CTLA-4 genotype relationship
patterns. Moreover, the results were significant when the case sub-
cohort was analyzed separately, and overlapped with the patterns
identified using differences of distances from the combined
analysis.
For the analysis of CTLA-4 genotype relationship pattern
differences between the survival categories, we used a different
strategy to make sure that what was found was indeed significant.
We defined an overall survival threshold and separated the cohort
into patients who lived longer or shorter than the selected
threshold. We then ran the complete analysis described below and
compared the statistical significance and performed logistic
regression models to recognize the survival categories from the
D ijð Þ. We systematically iterated through a threshold of 800 days
to a threshold 1900 days, and found the optimal threshold at
1820 days (5 years). This threshold separated the cohort into
balanced sub cohorts of 145 shorter and 137 longer surviving
patients.
We then computed the D ijð Þ separately for both these survival-
defined sub cohorts and tested the distributions of the results for all
190 CTLA-4 reference relationship pattern pairs. Out of the 190,
only 4 combinations resulted in the statistically significantly
different means of these distributions (see p-value Table 2). Here,
RRP10 reference pattern is the common context in all these
CTLA-4 genotype relationship patterns, which are significantly
biased between the longer and shorter surviving melanoma
patients. Similar interpretation is now possible for the localization
of the typical CTLA-4 genotype relationship patterns for these
outcome different patients: For example, shorter surviving patients
have typically positive D ijð Þ for RRP82RRP10, so they are closer
to RRP8, meaning that their CTLA-4 genotype tend to converge
to 4 minor, one heterozygous and one major allele (see Figure 9).
Similar interpretation is possible for remaining significantly
different genotype pattern pairs: RRP102RRP13 pairing have
typically zero D ijð Þ for shorter surviving patients, and positive for
longer survivals, indicating that RRP10 pattern with 4 major and 2
heterozygous alleles provides better functioning CTLA-4. Note
that – contrary to genotype profiles with conserved allelic states of
CTLA-4 polymorphisms – the CTLA-4 genomic profiles typical
for cases-only cohort describe states of mixed allelic states of the six
polymorphisms. For (CT318-AG49-CT60-JO30-JO27) profile,
the RRP8 has (a-a-b-ab-ab-a) allelic pattern, for RRP10 it is
(a-a-ab-a-a-ab) pattern.
Similar interpretation is possible for remaining significantly
different genotype pattern pairs: RRP10-RRP13 pairing have
typically zero for shorter surviving patients, and positive for longer
survivals, indicating that RRP10 pattern with 4 major and 2
heterozygous alleles provides better functioning CTLA-4. Note
that – contrary to genotype profiles with conserved allelic states of
CTLA-4 polymorphisms – the CTLA-4 genomic profiles typical
for cases-only cohort describe states of mixed allelic states of the six
polymorphisms. For (CT318-AG49-CT60-JO30-JO27) profile,
the RRP8 has (a-a-b-ab-ab-a) allelic pattern, for RRP10 it is (a-
a-ab-a-a-ab) pattern. These results allow characterization of the
odds for overall survival shorter than 5 years for new patients with
known status of six CTLA-4 SNP’s. We implemented this
computation into a Excel worksheet, which is available as
Table S1, together with instructions for its use (Manual S1).
Discussion
Using a novel approach to the analysis of SNP results for the
CTLA4 gene, we have hypothesized that recognition of melanoma
risk genotype profile requires an added dimension of analysis. This
second step in the analysis progression moves from analyzing the
means and variance of independent SNPs to analyzing the
distributions of differences of individual CTLA-4 genotype profiles
in the studied cohorts, in reference to normative reference profiles.
We argue that the observed haplotypes are the proper reference
for this purpose, and that we need to use them to account for
interpersonal variability in CTLA-4 genotype profiles. The
approach generates 6-partite graphical depictions which are based
upon algorithms that identified the same haplotypes and their
frequencies in established statistical procedures. Importantly, this
Figure 8. Comparison of CTLA-4 genotype relationship profiles
of five most case-control discriminating RRP’s. RRP2 (dashed
edges) is shown in both panels for reference. Symbols as in Fig. 1.
doi:10.1371/journal.pone.0086375.g008
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algorithm has shown that the haplotypes are not markers by
themselves, but rather that their averaged constructs, identifying
common co-occurrences of CTLA-4 SNPs in case and control
cohorts are useful. Having both personal CTLA-4 genotype
profiles and the normative reference co-occurring CTLA-4 SNP
haplotype patterns represented by the K-partite graphs has two
main advantages:
A. It determines from the data used to construct the g and
through the decomposition algorithm we developed from the
statistical conditions used in general characterization of haplotype
the actual TOTAL number of haplotypes in the cohort (8 in both
our cohorts). Considering that the theoretical number of
haplotypes for g is 64, this is an important data reduction
outcome of this approach. We know from other applications that
in cases where deconstructed 6-partite graphs are close to random
distributions of the conditional probabilities, the number of
components needed to fully deconstruct the model increases
significantly. Thus, small number of components in the g
deconstruction implies the commonality/regularity in the
CTLA-4 genotype profile composition and frequency in our study
population. This is in agreement with the previous study results.
B. The component graphs rrpi are data-driven, information-
rich references for exact quantitative computation of the ~dj
descriptors, which are tools enabling to change the focus of the
analysis from means and averages to where we need it (i.e. towards
differentiating features). Importantly, the rrpi’s are not just
mathematical constructs, but have well-defined genomic meaning,
being haplotypes. This facilitates clinically relevant interpretation
of the results in general and the individual (personalized) disease
related markers in particular. Results validate the hypothesis.
Another important aspect of this work is its ‘‘translation’’ of the
main molecular result of this paper to design of tools and
algorithms that use the relationship-patterns between genotyped
CTLA-4 variants to enable differential outcome analysis. Our
approach allows to show, that in the relationship patterns picture
of the individual CTLA-4 genotype, differential outcome can be
caused by a ‘‘majority rule’’, understood as a larger than critical
deviation from an ideal, reference haplotype relationship pattern.
Thus, same impact can be observed for different combinations of
the personal CTLA-4 variants, which is clearly quantitatively
captured in our NPS (relationship) based analysis, but causes
problems in conventional approaches. This sharing of a certain
level of differences from a reference normative pattern is very
specific in relation to the kinds of patterns that share a particular
property. This linkage of several heterogeneous patterns to one
‘‘functional’’ patient’s individual difference is that other side of
clinical data understanding, which can be brought to the plate
using this approach.
Without the pattern-based approach, we would never recognize
the relationship between those patterns and could not ask what is
unique about them. More importantly, this common distance of
personal CTLA-4 genotype profiles from reference genotype
patterns may group patients that would conventionally not have
been thought to be potentially grouped for interpretation. By
definition, they have different patterns of CTLA-4 parameters, the
conventional approach will tell you that these are different, so that
you would never ask whether they have something in common.
Our approach – by contrast – has brought together patients
with five different CTLA-4 genotypes so that we are forced to ask
what these patterns have in common. We can now clearly identify
that the absence of one common pattern from these five
different, is what distinguishes cases and controls.
The combination of SNP’s, shared by all individual patients’
profiles that satisfy the condition of having the largest distance
from one specific haplotype allows then discussing the mechanistic
details in future studies (for example, why it is just this combination
of major and minor allele in the 6 genotyped loci, which separates
cases from healthy controls).
We also see how NPS helps in extracting collective properties of
the CTLA-4 genotype through RRP’s characterizing different
cohorts. In the processing of complete study data, i.e. from the
subject set where about 50% are healthy controls, we observe
clearly the dominance of ‘‘allelic uniformity’’ of the CTLA-4
Figure 9. Comparison of RRP’s, distances from which are most
significantly different in the two survival groups (overall
survival longer or shorter than 5 years). RRP10 is shown by solid
edges in both panels (a,b) for reference.
doi:10.1371/journal.pone.0086375.g009
Table 2. p-values for difference in mean difference
distributions for distances of PRP’s from RRP’s pairs,
differentiating two survival groups (longer and shorter than
5 years).
RRP combination p-values
RRP8–RRP10 0.022
RRP10–RRP13 0.024
RRP10–RRP16 0.025
RRP10–RRP15 0.043
doi:10.1371/journal.pone.0086375.t002
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landmarks (RRP’s in Fig. 8). On contrary, when only melanoma
case sub-cohort is analyzed, the resulting characteristic CTLA-4
genotype RRP’s patterns, that are separate the long and short
survival categories (Fig. 9) are indicating that for melanoma cases,
the ‘‘allelic heterogeneity’’ dominates the functionally relevant
CTLA-4 genotype status.
Key issue is that detailed characterization of the genotype by
explicit consideration of the actual state of each SNP provides the
significant clustering (for one survival group) or difference/
distance (for the other survival group) of the prp’s relatively to
perhaps interesting and interpretable CTLA-4 genotype relation-
ship patterns.
The limitations of this study are: (a) the size of the study cohort
and (b) the number of the SNPs studied. Consequently, we did not
fully exploit NPS to combine clinical and genomic information.
However, this study was an effort at proof of principle for NPS and
with this accomplished, these goals will now readily be undertaken.
Specifically we will attempt to identify a priori, the compensatory
and detrimental haplotypes through finding their function-related
positive and negative descriptors.
In summary: Pattern based polymorphism relationship
analysis revealed that in healthy controls, the context in which
the CTLA-4 and its genetic variants operates is compatible with
the genotype with relationship pattern with ‘‘consensus’’ alleles in
all six sites. While we see some relationship pattern differences
between long and short overall survival groups, these are not
independently recognized, we need to know who is long and who
is short surviving. To obtain really independent, statistically
significant, prediction of the long or short survival we thus need to
go one additional step: consider that there is coherence pattern
between assayed regions of CTLA-4 gene and that this coherence
pattern is affected by the polymorphisms in the personal genotype
in exactly computable way. This is provided by the categorization
of disease outcome via analysis of thermodynamic changes in the
in CTLA-4 SNPs discovered by entromics [19], and quantified by
the differences in matrices that quantify the energy weights
associated with the various genotype profiles in individual patient
entromic coherence networks.
Supporting Information
Figure S1 Iterative algorithm steps involved in decom-
position of study graph g into rrp’s. Shown are residual
graphs after greedy removal of respective reference relationship
patterns in the order of their decreasing multiplicity.
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File S1 Algorithm for the identification of haplotypes.
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Manual S1 Instructions for using the Excel worksheet
implementation of CTLA-4 allelic patter based survival
category prognosis model for melanoma patients.
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Table S1 Excel worksheet implementation of the cate-
gorization of melanoma patients into shorter/longer
survival subgroups using distances between personal
and reference allelic patterns of six CTLA-4 polymor-
phisms studied in this paper.
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